- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01828346
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 1b/2a, open-label, non-randomized study in male and female subjects with MDS who are naïve, refractory or have relapsed to 5-Azacitidine therapy.
Primary Objective is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose, and pharmacodynamics (PD) of birinapant (TL32711) when administered in combination with 5-azacitidine (5 AZA) in subjects with myelodysplastic syndrome (MDS) who are naïve, refractory or have relapsed to 5-AZA therapy.
Secondary Objectives are to determine the clinical activity using the International Working Group (IWG) (Cheson, 2006) Response Criteria for MDS during the Phase 1b dose escalation stage of the study and in the Phase 2a expansion cohort, to determine the pharmacokinetics (PK) of birinapant when administered with 5-AZA in plasma and to assess exploratory translational biomarkers of anti-tumor activity of birinapant in combination therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Glendale, Arizona, United States, 85304
- Palo Verde Hematology Oncology
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic Scottsdale
-
-
California
-
Fresno, California, United States, 93720
- California Cancer Associates For Research and Excellence
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Jacksonville
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania, Abramson Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas M.D. Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women more than 18 years of age.
- Patients with high-risk Myelodysplastic Syndrome
- Performance status of greater or equal to 2 by the Eastern Cooperative Oncology Group (ECOG) scale.
- Subjects with high-risk MDS who are naïve to 5-Azacitidine or have previously received 5-AZA or decitabine as first-line cytotoxic therapy. Subjects with prior 5-Azacitidine therapy were evaluated to be either refractory or relapsed as determined by the Investigator, according to IWG response criteria.Subjects with relapsed or refractory disease may have only received prior 5-Azacitidine or decitabine.
- Hydroxyurea for patients with rapidly proliferative disease can be used up to 24 hours prior to therapy but not concomitantly with 5-Azacitidine.
- Adequate liver, pancreatic and renal function.
- Women of childbearing potential must have a negative serum pregnancy test at screening within 48 hours prior to the first dose
- Women of childbearing potential must agree to use 2 methods of adequate contraception
Exclusion Criteria:
- Subjects with life-threatening toxicity or non tolerability to prior 5-Azacitidine therapy.
- Subjects with hypoplastic Myelodysplastic syndrome.
- Subjects with >30% bone marrow blast cells.
- Subjects with malignant hepatic tumors or secondary malignancy within 2 years
- Known diagnosis of human immunodeficiency virus or chronic active Hepatitis B or C.
- Uncontrolled hypertension
- Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications,
- QT interval corrected for heart rate (QTcB) more than 480 msec
- Lack of recovery of prior adverse events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events version 4) (except alopecia) due to therapy administered prior to the initiation of study drug dosing.
- Nursing or pregnant women.
- Known allergy to any of the formulation components of birinapant.
- Known or suspected hypersensitivity to 5-Azacitidine or mannitol.
- Any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation.
- History of Bell's Palsy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
5-Azacitidine plus birinapant
|
Dose escalation part: (Drug escalation dose levels)
Other Names:
Dose Level (0) - 75mg/m2 daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose (MTD)
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TL32711-0087
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndrome
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Thomas Jefferson UniversityAbbVieRecruitingMyelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic SyndromeUnited States
-
Uma BorateRecruitingTherapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic SyndromeUnited States
-
University Hospital, BrestRecruitingMyelodysplastic Syndromes | Myelodysplastic Syndrome With Isolated Del(5Q) | Myelodysplastic Syndrome With Del(5Q)France
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
I-Mab Biopharma Co. Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
Clinical Trials on Birinapant
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedAcute Myelogenous LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedFallopian Tube Neoplasms | Peritoneal Neoplasms | Epithelial Ovarian CancerUnited States
-
TetraLogic PharmaceuticalsCompleted
-
TetraLogic PharmaceuticalsCompleted
-
TetraLogic PharmaceuticalsCompletedRelapsed Epithelial Ovarian Cancer | Relapsed Primary Peritoneal Cancer | Relapsed Fallopian Tube CancerUnited States
-
MedivirMerck Sharp & Dohme LLCTerminated
-
TetraLogic PharmaceuticalsTerminated
-
TetraLogic PharmaceuticalsTerminatedChronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)United States, Spain, Australia, Germany
-
National Cancer Institute (NCI)TerminatedLocally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell CarcinomaUnited States
-
Novartis PharmaceuticalsActive, not recruitingEGFR-mutant Non-small Cell Lung CancerTaiwan, Germany, Canada, Italy, Singapore, Hong Kong